Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Other Non-Current Assets (2021 - 2025)

Barinthus Biotherapeutics' Other Non-Current Assets history spans 5 years, with the latest figure at $930000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 5.56% year-over-year to $930000.0; the TTM value through Dec 2025 reached $930000.0, up 5.56%, while the annual FY2025 figure was $930000.0, 5.56% up from the prior year.
  • Other Non-Current Assets reached $930000.0 in Q4 2025 per BRNS's latest filing, up from $138000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.1 million in Q3 2023 to a low of $138000.0 in Q3 2025.
  • Average Other Non-Current Assets over 5 years is $861055.6, with a median of $894000.0 recorded in 2022.
  • Peak YoY movement for Other Non-Current Assets: soared 30.46% in 2023, then tumbled 85.1% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $804000.0 in 2021, then increased by 21.39% to $976000.0 in 2022, then dropped by 9.63% to $882000.0 in 2023, then fell by 0.11% to $881000.0 in 2024, then rose by 5.56% to $930000.0 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Other Non-Current Assets are $930000.0 (Q4 2025), $138000.0 (Q3 2025), and $944000.0 (Q2 2025).